Cortexin: The Russian Neuropeptide Used in Stroke Care That Western Researchers Have Never Heard Of

Walk into a neurological ward at a Russian hospital after a stroke and you will likely find Cortexin in the treatment protocol. It has been there since 1982. Administered as an intramuscular injection at 10 mg per day for 10 consecutive days, sometimes repeated, Cortexin is as routine in Russian neurology as tPA is in Western stroke care, though they serve different functions.

Western neurologists have almost certainly never heard of it. A search of major English-language neurology journals returns essentially nothing on Cortexin. A PubMed search for "Cortexin neuropeptide" returns only 5 results, almost all in Russian journals with English abstracts. Yet there are decades of clinical experience, published case series, and several randomized comparative studies in Russian-language literature that document its neurological effects.

This information gap is not a Western judgment that Cortexin does not work. It is simply a language and access barrier. The research exists, the clinical data exists, and the compound has been reviewed and approved by Russian regulatory authorities multiple times over four decades. English-speaking researchers who care about neuroprotective peptides should know about it.

Cortexin is produced by enzymatic hydrolysis of bovine cerebral cortex, followed by purification and lyophilization to yield a standardized polypeptide mixture. The final product contains low-molecular-weight peptides in the 1-10 kDa range. It is the cortical-tissue analog of Cerebrolysin (which is derived from whole porcine brain).

The biological activity profile documented in published research includes:

Neurotrophic activity: Cortexin contains peptide fragments with BDNF-like, NGF-like, and CNTF-like activity in neuronal bioassays. These peptides promote neuronal survival, support axonal growth, and protect against excitotoxicity in cell culture models.

Antioxidant activity: Published studies document Cortexin reducing lipid peroxidation products and increasing antioxidant enzyme activity (SOD, catalase) in brain tissue from stroke and TBI models.

Tissue-specific enrichment: The cerebral cortex origin of Cortexin means the peptide mixture is enriched for regulatory sequences naturally present in cortical neurons. Khavinson's bioregulator theory predicts these cortex-derived peptides have particular efficacy in cortical tissue versus peptides from other brain regions. Whether this tissue specificity is mechanistically real or theoretical remains an open research question.

Neuroprotection: In rodent ischemia-reperfusion models, Cortexin administration reduces infarct volume, improves neurological deficit scores, and promotes survival of neurons in the penumbra.

The most important English-language publication on Cortexin is the 2019 study by Zhang et al. in the Journal of Neurological Sciences comparing Cortexin, Cerebrolysin, Cognistar (another brain hydrolysate), and a fourth preparation in a rat embolic stroke model.

This randomized, blinded, placebo-controlled study enrolled adult male Wistar rats with embolic middle cerebral artery occlusion. Daily IP administration of each compound began 24 hours after stroke and continued for 28 days. Primary outcomes were neurological deficit score (modified Neurological Severity Score, mNSS), lesion volume by MRI, and histological analysis of penumbra neuronal density.

Key findings: All active treatment groups (Cortexin, Cerebrolysin, and comparators) showed statistically significant improvements in neurological function versus placebo at 28 days. Lesion volumes were significantly reduced versus placebo in all active groups. Neuronal survival in the penumbra was significantly higher in all active treatment groups. No significant differences between Cortexin and Cerebrolysin were detected on any primary endpoint.

The conclusion the authors drew is notable: the neuropeptide preparations derived from different brain tissue sources produced comparable neurological outcomes, suggesting the neurotrophic activity of brain hydrolysates is not highly specific to tissue source. This finding is relevant to the broader debate about whether the specific organ origin of bioregulator peptides matters for efficacy.

The Russian clinical literature on Cortexin is primarily in the journal Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (the Journal of Neurology and Psychiatry named after S.S. Korsakov), the leading Russian-language neurology journal. Publications in English exist only as abstracts or through translation databases.

Across published Russian clinical reports, Cortexin use in the following conditions has been documented:

Ischemic stroke: Multiple clinical series reporting improved neurological recovery (Barthel Index, NIHSS) in patients receiving Cortexin versus historical controls or comparative treatment groups. The standard protocol is 10 mg IM daily for 10 days, sometimes with a second course at 3 months.

Traumatic brain injury (TBI): Cortexin is used in the acute phase of TBI for neuroprotection and in the recovery phase for cognitive rehabilitation. Published series report improvements in Glasgow Outcome Scale scores and cognitive test performance.

Epilepsy: Small studies report Cortexin as an adjunct in epilepsy management, particularly in children, with reported reductions in seizure frequency and cognitive improvements.

Age-related cognitive decline: Used in Russian geriatric clinics for mild cognitive impairment and dementia, with published reports of cognitive test score improvements.

For Western researchers familiar with Cerebrolysin and Semax, Cortexin occupies a middle position:

For researchers interested in including Cortexin in comparative neuropeptide studies, the Zhang 2019 paper provides a validated head-to-head design using Cerebrolysin as the reference standard. The lack of significant differences between Cortexin and Cerebrolysin in that study suggests they could be used interchangeably in models where total neurotrophic support is the variable of interest.